Core Viewpoint - Ganli Pharmaceutical has received approval from the National Medical Products Administration for its investigational drug GLR1044 injection, a biosimilar to Dupixent (dupilumab), aimed at treating moderate to severe atopic dermatitis in adults [1] Group 1 - Ganli Pharmaceutical's wholly-owned subsidiary in Shandong has been granted a clinical trial approval notice for GLR1044 injection [1] - GLR1044 injection is intended for patients with inadequate control or for whom topical prescription medications are not recommended [1] - As of September 30, 2025, Ganli Pharmaceutical has invested a total of 65.7245 million RMB in the GLR1044 project [1]